NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

10x Genomics, Inc. (TXG) Stock Analysis

10x Genomics, Inc. (TXG) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

TXG

$62.65

−$0.57 (−0.90%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TXG with… →

TXG Key Statistics

As of Sep 4, 2026
Trading
Open
$62.54
Previous Close
$63.22
Day's Range
60.99–63.48
52-Week Range
11.16–66.94
Volume
1.47M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.08
Valuation
Market Cap
$8.16B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
308.12
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
13.23
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.59
Financials (FY)
Revenue (FY)
$642.82M+5.25%
Net Income (FY)
−$43.54M
Profit marginThe share of revenue left as profit after all costs and taxes.
−12.18%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
120.21M
1-Year Return
+361.68%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
3.16M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TXG Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+284.12%
2025+13.58%
2024−74.34%
2023+53.57%
2022−75.54%
2021+5.20%
2020+85.70%
2019 (partial year)+44.55%

As of September 4, 2026.

TXG Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$642.82M−$43.54M−6.8%
2024$610.79M−$182.63M−29.9%
2023$618.73M−$255.10M−41.2%
2022$516.41M−$166.00M−32.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$642.82M$443.88M−$110.89M−$43.54M−6.8%
2024$610.79M$414.48M−$194.56M−$182.63M−29.9%
2023$618.73M$409.31M−$204.35M−$255.10M−41.2%
2022$516.41M$396.02M−$167.94M−$166.00M−32.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TXG Valuation vs Medical Devices Median

Median of 151 stocks
MetricTXGMedical Devices medianvs median
P/S ratio13.232.984.4x the median
Profit margin−12.18%−1.69%10.5 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values 10x Genomics, Inc. (TXG) at $8.16B. The company sits in the Healthcare sector, in the Medical Devices industry. The company reports 1,178 employees.

Over the past 52 weeks the price has ranged from $11.16 to $66.94. The most recent close on file for TXG is $62.65, dated September 4, 2026. That is −$0.57 (−0.90%) against the previous close. The latest close sits 461.38% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $642.82M. Against the prior fiscal year total of $610.79M, that is a change of +5.25%. The same year closed with a net loss of $43.54M. Profit margin runs at −12.18%. That is 10.5 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −0.59.

Across the 4 fiscal years on file, revenue moves from $516.41M in 2022 to $642.82M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 308.12. The price-to-sales ratio is 13.23. On price-to-sales that is 4.4 times the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 2.08. Annualized volatility over the trailing 7 years is 67.29%. The trailing one-year price return is +361.68%. Measured over 5 years, that is −19.49% a year compounded.

Growth & Income

No dividend is on file for TXG.

2026 is still running; the price is +284.12% year to date. The strongest complete calendar year on file is 2020 at +85.70%; the weakest is 2022 at −75.54%. Of the 6 complete calendar years on file, 4 finished higher.

Peer Comparison

10x Genomics, Inc. (TXG) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
10x Genomics, Inc. TXG $8.16B —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. 10x Genomics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About 10x Genomics, Inc.

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Visit website →